Saturday, January 27, 2018

NCORP Director Discusses Upcoming Mammography Screening Trial.

Healio (1/27, Southall) reported on a planned “NCI-supported trial” that “will compare tomosynthesis – or 3-D mammography – with conventional 2-D mammography for the screening of breast cancer in asymptomatic women.” The Tomosynthesis Mammographic Imaging Screening Trial will be “the first randomized trial designed to determine if one digital mammography methodology is superior to the other.” The trial is anticipated “to enroll 165,000 asymptomatic women aged 45 to 74 years, and nearly 100 mammography clinics in the United States are expected to participate.” In a press release, Worta McCaskill-Stevens, MD, director of the NCI Community Oncology Research Program (NCORP), said, “The evolution of mammography technology provides us with an opportunity to fill in the gaps in our knowledge about two available breast cancer screening tests.” The article also included an interview with McCaskill-Stevens, where she discusses the differences between screening modalities, the reasons for the planned trial, and the anticipated date when trial results might be available.

Editor’s Note: The trial is coordinated through the American College of Radiology (ACR) Center for Research and Innovation.

Author: Nicole Hardy

Categories: 2018, January, News, Screening and MammographyNumber of views: 6821